March 14 Product: Madrigals Rezdiffra Indication: MASH In one of the years most highly anticipated FDA decisions, Madrigal Pharmaceuticals won approval Thursday for resmetiromhenceforth to be known as Rezdiffraas the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH), formerly noncirrhotic non-alcoholic steatohepatitis (NASH)
The FDA's Pharmacy Compounding Advisory Committee meets July 2324 to review BPC-157, KPV and Epitalon for the 503A compounding list
When used in therapy, peptides can target the root causes of pain and promote long-term recovery
They do not predict response to tirzepatide, retatrutide, or any specific medication, but they can help map the baseline metabolic terrain a healthcare provider is working within
Food Chem Toxicol 59:339355
galanga inhibited the infiltration of leukocytes, especially eosinophils, in a mouse model of OVA-induced asthma